This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, J. Articles by Ohar, J. Search for Related Content PubMed PubMed Citation Articles by Xu, J. Articles by Ohar, J.

Association Studies of Serum Prostate-specific Antigen Levels and the Genetic Polymorphisms at the Androgen Receptor and Prostate-specific Antigen Genes¹

Center for Human Genomics [J. X., D. A. M., S. L. Z., E. R. B., J. O.] and Department of Cancer Biology [S. D. C.], Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157; Department of Urology, Washington University School of Medicine, St. Louis, Missouri 63110 [W. J. C.]; and School of Public Health [D. A. S.] and Department of Medicine [J. O.], St. Louis University, St. Louis, Missouri

Testing for serum prostate-specific antigen (PSA) levels has been widely used to screen for prostate cancer. However, PSA testing has low specificity and sensitivity because PSA is not prostate cancer-specific. PSA is encoded by the APS gene, and the expression of this gene is regulated by androgens. W. Xue et al. Cancer Res., 60: 839–841, 2000 reported recently that serum PSA levels are associated with a G/A polymorphism at androgen responsive element 1 (ARE1) of APS and/or the CAG repeats in exon 1 of the androgen receptor (AR) gene. This result, if confirmed, may significantly increase the specificity and sensitivity of PSA testing by incorporating genotype-specific thresholds. In this study, we tested for the association between serum PSA levels and these single nucleotide polymorphisms (SNPs) in a large sample of 518 men. For the AR gene, we observed slightly (but not statistically significant) higher mean serum PSA levels in men with shorter CAG repeats (21) or shorter GGC repeats (16). For the ARE1 of the APS, we found slightly (but not statistically significant) lower PSA levels in men with the AA genotype. It is worth noting that this observation is opposite to the findings of W. Xue et al. Cancer Res., 60: 839–841, 2000. We hypothesize that the effects of ARE1 and AR genotypes on mean PSA levels may reflect the effect of other causal polymorphisms in these genes, which are in linkage disequilibrium with these polymorphisms. A systematic approach is required to identify sequence variants in these genes and other related genes, and to test for an association between these variants and PSA levels in large samples.

This article has been cited by other articles:

				E. KALAY, A. ERGEN, F. NARTER, B. AGACHAN, U. GORMUS, N. YIGIT, and T. ISBIR ARE-I Polymorphism on PSA Gene in Prostate Cancer Patients of a Turkish Population Anticancer Res, April 1, 2009; 29(4): 1395 - 1398. [Abstract] [Full Text] [PDF]

				S. D. Cramer, J. Sun, S. L. Zheng, J. Xu, and D. M. Peehl Association of Prostate-Specific Antigen Promoter Genotype with Clinical and Histopathologic Features of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2451 - 2457. [Abstract] [Full Text] [PDF]

				J. Lai, M.-A. Kedda, K. Hinze, R. L.G. Smith, J. Yaxley, A. B. Spurdle, C.P. Morris, J. Harris, and J. A. Clements PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility Carcinogenesis, May 1, 2007; 28(5): 1032 - 1039. [Abstract] [Full Text] [PDF]

				G. Severi, V. M. Hayes, P. Neufing, E. J.D. Padilla, W. D. Tilley, S. A. Eggleton, H. A. Morris, D. R. English, M. C. Southey, J. L. Hopper, et al. Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1142 - 1147. [Abstract] [Full Text] [PDF]

				W. Wang, E. M. John, and S. A. Ingles Androgen Receptor and Prostate-Specific Antigen Gene Polymorphisms and Breast Cancer in African-American Women Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2990 - 2994. [Abstract] [Full Text] [PDF]

				R. K. Nam, W. W. Zhang, M. A.S. Jewett, J. Trachtenberg, L. H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S. A. Narod The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy Clin. Cancer Res., December 1, 2005; 11(23): 8391 - 8397. [Abstract] [Full Text] [PDF]

				M. S. Cicek, X. Liu, G. Casey, and J. S. Witte Role of Androgen Metabolism Genes CYP1B1, PSA/KLK3, and CYP11{alpha} in Prostate Cancer Risk and Aggressiveness Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2173 - 2177. [Abstract] [Full Text] [PDF]

				R. K. Nam, W. W. Zhang, J. Trachtenberg, M. A. S. Jewett, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, et al. Comprehensive Assessment of Candidate Genes and Serological Markers for the Detection of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1429 - 1437. [Abstract] [Full Text] [PDF]

				S. D. Cramer, B.-L. Chang, A. Rao, G. A. Hawkins, S. L. Zheng, W. N. Wade, R. T. Cooke, L. N. Thomas, E. R. Bleecker, W. J. Catalona, et al. Association Between Genetic Polymorphisms in the Prostate-Specific Antigen Gene Promoter and Serum Prostate-Specific Antigen Levels J Natl Cancer Inst, July 16, 2003; 95(14): 1044 - 1053. [Abstract] [Full Text] [PDF]

				B. J. Duggan, J. J. McKnight, K. E. Williamson, M. Loughrey, D. O'Rourke, P. W. Hamilton, S. R. Johnston, C. C. Schulman, and A. R. Zlotta The Need to Embrace Molecular Profiling of Tumor Cells in Prostate and Bladder Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1240 - 1247. [Abstract] [Full Text] [PDF]